The French Sanofi also chooses Spain to carry out her clinical trials. Currently, the company is investigating a drug related to a matter in which Spain has been a world leader for 33 years: transplants.
This is Belumosudil, a molecule to treat the graft disease against receiver, the most frequent complication of marrow transplants. It is a pathology triggered by an immune response of donor cells against healthy tissues of the receiver. Between effects, inflammation and fibrosis stand out in multiple organs, causing functional limitation, decreased quality of life and causing death.
Until now, this pathology has been treated with corticosteroids. So things, this drug is being tested in Spain for different indications, and research has been deployed in nine centers, among which are the Regional Hospital of Malaga, the University Hospital Virgen del Rocío de Sevilla, the University Hospital of Salamanca, the University and Polytechnic Hospital of the Fe Valencia and the Niño Jesús University Hospital of Madrid, among others.
Approval at the end of 2025
Currently, one of Belumosudil’s instructions is already in the hands of the European Medication Agency (EMA), so Sanofi expects Europe to approve this drug by the end of this year. It has already been approved by regulatory agencies for use in the United States, Canada and the United Kingdom.
The transplant of stem cells or bone marrow transplant is a type of treatment that can be used to treat some types of blood cancer, such as certain types of leukemia, lymphomas or multiple myeloma. Between 30 and 80% of patients present the host graft disease chronic, while up to 70% their acute form.
#SANOFI #Test #Spain #treatment #frequent #complication #type #transplant
